These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22237659)
1. Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. Catalano V; Vincenzi B; Giordani P; Graziano F; Santini D; Baldelli AM; Alessandroni P; Schiavon G; Rossi D; Casadei V; D'Emidio S; Luzi Fedeli S; Tonini G; Fiorentini G Gastric Cancer; 2012 Oct; 15(4):419-26. PubMed ID: 22237659 [TBL] [Abstract][Full Text] [Related]
2. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY Oncology; 2002; 63(3):239-47. PubMed ID: 12381903 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927 [TBL] [Abstract][Full Text] [Related]
4. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R Tumori; 2010; 96(1):48-53. PubMed ID: 20437857 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Li CP; Chen JS; Chen LT; Yen CJ; Lee KD; Su WP; Lin PC; Lu CH; Tsai HJ; Chao Y Br J Cancer; 2010 Oct; 103(9):1343-8. PubMed ID: 20924378 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287 [TBL] [Abstract][Full Text] [Related]
7. Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma. Alici S; Buyukberber S; Alkis N; Benekli M; Ozkan M; Bilici A; Demirci U; Karaca H; Arpaci E; Gumus M; Altunbas M; Dane F; Turk HM; Asian Pac J Cancer Prev; 2013; 14(1):423-7. PubMed ID: 23534766 [TBL] [Abstract][Full Text] [Related]
8. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039 [TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718 [TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Anter AH; Abdel-Latif RM Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258 [TBL] [Abstract][Full Text] [Related]
13. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Constenla M; Garcia-Arroyo R; Lorenzo I; Carrete N; Campos B; Palacios P Gastric Cancer; 2002; 5(3):142-7. PubMed ID: 12378340 [TBL] [Abstract][Full Text] [Related]
14. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Lorenzen S; Hentrich M; Haberl C; Heinemann V; Schuster T; Seroneit T; Roethling N; Peschel C; Lordick F Ann Oncol; 2007 Oct; 18(10):1673-9. PubMed ID: 17660494 [TBL] [Abstract][Full Text] [Related]
15. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764 [TBL] [Abstract][Full Text] [Related]
17. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868 [TBL] [Abstract][Full Text] [Related]
18. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Inal A; Kaplan MA; Kucukoner M; Isikdogan A Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]